Search clinical trials for: Placebo-rituximab

Total 56780 results

University of Cagliari
Azienda Ospedaliero Universitaria di Cagliari

Recruiting

BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis (PREDICT)

Rheumatoid Arthritis | Systemic Lupus Erythematosus | BLyS Polymorphism

Italy
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH); Fogarty...

Completed

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

HIV | Diffuse Large B-cell Lymphoma

Malawi
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402

Lymphoma
Stanford University

Completed

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Transformed Lymphoma | Other Subtypes of B-cell Lymphoma

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States, Puerto Rico, South Africa
Eben Rosenthal

Terminated

Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Gynecologic Oncology Group
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Cervical Cancer

United States
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
Institut Paoli-Calmettes

Completed

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma (R2)

Non-Hodgkin Lymphoma

France
Roswell Park Cancer Institute
Celgene

Completed

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Lymphoma | Leukemia
Assistance Publique - Hôpitaux de Paris

Completed

Rituximab in Systemic Sclerosis (RECOVER)

Systemic Sclerosis

France
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

China
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Nantong University; Tianjin Medical University Second... and other collaborators

Unknown

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)

China
University of Arizona
National Cancer Institute (NCI)

Completed

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma (VCR)

Lymphoma | Mantle Cell Lymphoma | Indolent Lymphoma | SLL

United States
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
Hoffmann-La Roche

Completed

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

Spain, France, United Kingdom, Netherlands, Italy
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

Head and Neck Squamous Cell Carcinoma
Heidelberg University
Merck KGaA, Darmstadt, Germany; University Hospital Heidelberg; Dept. of Radiation...

Unknown

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (ACCEPT)

Adenoid Cystic Carcinoma

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Active, not recruiting

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
Gruppo Oncologico del Nord-Ovest

Completed

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (MACBETH)

Metastatic Colorectal Cancer

Italy
University Medical Center Groningen
Erasmus Medical Center

Completed

Image Guided Penile Cancer Surgery (GLANS)

Penile Cancer | Margin Assessment

Netherlands
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC (ELANFIT)

Metastatic or Recurrent Head and Neck Squamous Cell Cancer

France
Yale University

Withdrawn

Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer

Colorectal Cancer
Merck KGaA, Darmstadt, Germany

Completed

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Colorectal Neoplasms

Korea, Republic of
Samsung Medical Center

Completed

Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis

Colorectal Cancer | Unresectable Liver Metastasis

Korea, Republic of
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Withdrawn

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom (Z-BEAM LDGGB)

Non-Hodgkin's Lymphoma

Spain
German Low Grade Lymphoma Study Group

Terminated

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma (R-GO)

Indolent Lymphoma

Germany
University of Giessen

Completed

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Lymphoma

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

United States
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Ann Arbor Stage II Non-Hodgkin Lymphoma

United States
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (PMS LAD SCCHN)

Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHN

India
Groupe Oncologie Radiotherapie Tete et Cou
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (TPEx)

Squamous Cell Head and Neck Carcinoma | Recurrent or Metastatic Disease

France, Belgium
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Maastricht Radiation Oncology
Amsterdam UMC, location VUmc

Completed

Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients (Cetuximab Zr89)

Stage IV Cancer

Netherlands
Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
Fudan University

Completed

Study of Cetuximab to Treat Gastric Cancer (STAGE)

Gastric Cancer

China
Eye & ENT Hospital of Fudan University

Recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Locally Advanced Hypopharyngeal Carcinoma

China
Pfizer

Completed

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Lymphoma, B-Cell

Japan
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma

Lymphoma

Search clinical trials for: Placebo-rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations